GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

GRAIL (Nasdaq: GRAL) granted inducement equity awards of restricted stock units covering an aggregate of 19,500 shares to 20 newly hired non-executive employees under its Inducement Equity Incentive Plan dated March 2, 2026.

The RSUs vest over approximately four years, with 25% vesting Feb. 28, 2027 and the remainder vesting on each annual anniversary thereafter, subject to continued employment.

Key Figures

RSU shares granted: 19,500 shares Employees receiving RSUs: 20 employees Initial vesting tranche: 25% +1 more

4 metrics

RSU shares granted 19,500 shares Inducement RSUs under equity incentive plan

Employees receiving RSUs 20 employees Recently hired non-executive staff

Initial vesting tranche 25% Portion of RSU award vesting on Feb. 28, 2027

Vesting period 4 years RSUs vest over approximately four years

Market Reality Check

Price: $52.63 Vol: Volume 1,744,291 is below...

normal vol

$52.63 Last Close

Volume Volume 1,744,291 is below the 20-day average of 2,049,571 ahead of this announcement. normal

Technical Shares at 53.23 are trading below the 200-day MA of 64.98 and well under the 52-week high of 118.84.

Peers on Argus

GRAL fell 8.38% while key peers showed mixed, modest moves (e.g., NEOG +0.54%, T...

1 Up

GRAL fell 8.38% while key peers showed mixed, modest moves (e.g., NEOG +0.54%, TWST -1.16%, OPK +0.84%, NEO -1.01%, CDNA +1.13%), indicating stock-specific pressure rather than a sector-wide move.

Common Catalyst Only one peer (NEOG) reported notable news on a business divestiture, with no clear common theme tied to GRAL’s inducement grants.

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Conference presentation	Positive	+2.9%	Announcement of management presentation at TD Cowen health care conference.
Feb 19	Earnings results	Negative	-50.5%	Q4 and 2025 results with strong growth but large net losses reported.
Feb 19	Clinical trial data	Negative	-50.5%	NHS-Galleri trial missed primary endpoint despite favorable secondary findings.
Feb 16	Earnings date set	Neutral	+1.6%	Scheduled date and webcast details for Q4 and full‑year 2025 results.
Jan 29	Regulatory filing	Positive	-3.1%	Submission of final PMA module for Galleri multi‑cancer detection test.

Pattern Detected

Recent major fundamental and clinical updates often led to sharp moves, with generally aligned reactions; regulatory progress (PMA filing) previously saw a mild negative divergence.

Recent Company History

Over recent months, GRAIL highlighted several key milestones. On Jan 29, 2026, it submitted the final PMA module for Galleri, using data from PATHFINDER 2 and NHS-Galleri. An Feb 19, 2026 earnings release showed $43.6M Q4 and $147.2M 2025 revenue but a large net loss, coinciding with NHS-Galleri topline data and a -50.55% move. Conference participation on Feb 24 and the earlier earnings-date notice saw modest gains. Today’s small inducement grants contrast with these earlier, more material catalysts.

Market Pulse Summary

This announcement details inducement RSU grants covering 19,500 shares to 20 newly hired non-executi...

Analysis

This announcement details inducement RSU grants covering 19,500 shares to 20 newly hired non-executive employees, vesting over about four years under Nasdaq Listing Rule 5635(c)(4). It represents routine equity-based hiring activity rather than a fundamental change. In context, recent news included major earnings, NHS-Galleri trial readouts, and a PMA submission. Investors may focus more on future clinical milestones, regulatory decisions, and revenue trends when assessing the company’s trajectory.

Key Terms

restricted stock units, RSUs, Nasdaq Listing Rule 5635(c)(4), Inducement Equity Incentive Plan

4 terms

restricted stock units financial

"granted equity awards in the form of restricted stock units ("RSUs") underlying an"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"form of restricted stock units ("RSUs") underlying an aggregate of 19,500 shares"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Nasdaq Listing Rule 5635(c)(4) regulatory

"agreement in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement plan"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

Inducement Equity Incentive Plan financial

"awards were granted under GRAIL's Inducement Equity Incentive Plan and related form"

An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.

AI-generated analysis. Not financial advice.

MENLO PARK, Calif., March 2, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 19,500 shares of GRAIL's common stock to 20 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting Feb. 28, 2027, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302701345.html

SOURCE GRAIL, Inc.

FAQ

What did GRAIL (GRAL) announce on March 2, 2026 about inducement grants?

GRAIL granted RSUs for an aggregate of 19,500 shares to 20 new non-executive hires as inducements. According to the company, awards were granted under its Inducement Equity Incentive Plan in line with Nasdaq Listing Rule 5635(c)(4).

How do the GRAIL (GRAL) inducement RSUs vest and when is the first vesting date?

The RSUs vest over about four years with 25% vesting on Feb. 28, 2027 as the first vest. According to the company, remaining portions vest on each one-year anniversary thereafter, subject to continued employment.

How many employees received inducement awards from GRAIL (GRAL) and what type of awards were granted?

GRAIL granted inducement awards to 20 recently hired non-executive employees in the form of restricted stock units. According to the company, the awards are governed by its Inducement Equity Incentive Plan and related award agreement.

Why did GRAIL (GRAL) use the inducement equity plan for these hires?

GRAIL used the inducement equity plan to provide material equity awards to individuals not previously employed by the company. According to the company, the plan is used exclusively for inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4).

Will the GRAIL (GRAL) inducement RSUs vest if an employee leaves before the vesting dates?

The RSUs vest only while the employee remains employed through the vesting dates; leaving early generally forfeits unvested awards. According to the company, vesting is subject to continued employment with GRAIL or a successor/subsidiary through each vesting date.